27282265|t|The Benefits of Combination Therapy with Esomeprazole and Rebamipide in Symptom Improvement in Reflux Esophagitis: An International Multicenter Study
27282265|a|To investigate the effects of esomeprazole and rebamipide combination therapy on symptomatic improvement in patients with reflux esophagitis. A total of 501 patients with reflux esophagitis were randomized into one of the following two treatment regimens: 40 mg esomeprazole plus 300 mg rebamipide daily (combination therapy group) or 40 mg esomeprazole daily (monotherapy group). We used a symptom questionnaire that evaluated heartburn, acid regurgitation, and four upper gastrointestinal symptoms. The primary efficacy end point was the mean decrease in the total symptom score. The mean decreases in the total symptom score at 4 weeks were estimated to be -18.1±13.8 in the combination therapy group and -15.1±11.9 in the monotherapy group (p=0.011). Changes in reflux symptom s from baseline after 4 weeks of treatment were -8.4±6.6 in the combination therapy group and -6.8±5.9 in the monotherapy group (p=0.009). Over a 4- week treatment course, esomeprazole and rebamipide combination therapy was more effective in decreasing the symptoms of reflux esophagitis than esomeprazole monotherapy.
27282265	16	35	Combination Therapy	T058	UMLS:C0009429
27282265	41	53	Esomeprazole	T103	UMLS:C0937846
27282265	58	68	Rebamipide	T103	UMLS:C0069562
27282265	72	79	Symptom	T033	UMLS:C1457887
27282265	95	113	Reflux Esophagitis	T038	UMLS:C0014869
27282265	132	149	Multicenter Study	T062	UMLS:C1096776
27282265	180	192	esomeprazole	T103	UMLS:C0937846
27282265	197	207	rebamipide	T103	UMLS:C0069562
27282265	208	227	combination therapy	T058	UMLS:C0009429
27282265	231	242	symptomatic	T033	UMLS:C1457887
27282265	272	290	reflux esophagitis	T038	UMLS:C0014869
27282265	321	339	reflux esophagitis	T038	UMLS:C0014869
27282265	345	355	randomized	T062	UMLS:C0206034
27282265	386	404	treatment regimens	T058	UMLS:C0040808
27282265	412	424	esomeprazole	T103	UMLS:C0937846
27282265	437	447	rebamipide	T103	UMLS:C0069562
27282265	455	474	combination therapy	T058	UMLS:C0009429
27282265	491	503	esomeprazole	T103	UMLS:C0937846
27282265	511	522	monotherapy	T058	UMLS:C0087111
27282265	541	548	symptom	T033	UMLS:C1457887
27282265	549	562	questionnaire	T170	UMLS:C0034394
27282265	578	587	heartburn	T033	UMLS:C0018834
27282265	618	649	upper gastrointestinal symptoms	T038	UMLS:C0857493
27282265	828	847	combination therapy	T058	UMLS:C0009429
27282265	876	887	monotherapy	T058	UMLS:C0087111
27282265	916	922	reflux	T038	UMLS:C0014869
27282265	923	930	symptom	T033	UMLS:C1457887
27282265	964	973	treatment	T058	UMLS:C0087111
27282265	995	1014	combination therapy	T058	UMLS:C0009429
27282265	1041	1052	monotherapy	T058	UMLS:C0087111
27282265	1085	1094	treatment	T058	UMLS:C0087111
27282265	1103	1115	esomeprazole	T103	UMLS:C0937846
27282265	1120	1130	rebamipide	T103	UMLS:C0069562
27282265	1131	1150	combination therapy	T058	UMLS:C0009429
27282265	1173	1183	decreasing	T033	UMLS:C0442797
27282265	1188	1196	symptoms	T033	UMLS:C1457887
27282265	1200	1218	reflux esophagitis	T038	UMLS:C0014869
27282265	1224	1236	esomeprazole	T103	UMLS:C0937846
27282265	1237	1248	monotherapy	T058	UMLS:C0087111